 |
||||
| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
*Department of Medicine, University of Melbourne, Austin & Repatriation Medical Centre (Repatriation Campus), Heidelberg West, Victoria, Australia; Department of Cell Biology, Institute of Nephrology, Niigata University School of Medicine, Niigata, Japan; Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, Virginia; and Novartis Pharma AG, Basel, Switzerland.
Correspondence to Dr. Zemin Cao, Department of Medicine, University of Melbourne, Austin & Repatriation Medical Centre (Repatriation Campus), Heidelberg West, Victoria 3081, Australia; Phone: 613-9496-2347; Fax: 613-9497-4554; E-mail: cao{at}austin.unimelb.edu.au
ABSTRACT. The role of the angiotensin type 2 (AT2) receptor in the pathogenesis of progressive renal injury has not been previously elucidated. The renal expression of the AT1 and AT2 receptors in subtotally nephrectomized rats (STNx) and the effects of AT2 receptor blockade on renal injury were explored. Reduced renal expression of the AT1 but not the AT2 receptor was observed in STNx by reverse transcription–PCR, by in vitro autoradiography, and by immunohistochemical staining. The STNx rats were randomly assigned to AT1 receptor antagonist valsartan, AT2 receptor antagonist PD123319, or the combination of both for 4 wk. Increased proteinuria in STNx rats was reduced by PD123319 but to a lesser degree when compared with valsartan. Reduced gene and protein expression of the slit diaphragm protein nephrin was prevented by either valsartan or PD123319. Expression of osteopontin, proliferating cell nuclear antigen, and monocyte/macrophage infiltration was increased in STNx rats and was reduced by both AT1 and AT2 receptor antagonists. These effects of AT2 receptor antagonism were observed in the presence of increased BP in STNx rats. These findings suggest that blockade of the AT2 receptor alone confers a degree of renal protection; in particular, it seems that the combination of the AT1 and AT2 receptor antagonists may confer additive renal effects than either receptor antagonist as monotherapy.
This article has been cited by other articles:
 |
|
 |
|
  K. Suzuki, G. D. Han, N. Miyauchi, T. Hashimoto, T. Nakatsue, Y. Fujioka, H. Koike, F. Shimizu, and H. Kawachi Angiotensin II Type 1 and Type 2 Receptors Play Opposite Roles in Regulating the Barrier Function of Kidney Glomerular Capillary Wall Am. J. Pathol., June 1, 2007; 170(6): 1841 - 1853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Okada, T. Inoue, T. Kikuta, Y. Watanabe, Y. Kanno, S. Ban, T. Sugaya, M. Horiuchi, and H. Suzuki A Possible Anti-Inflammatory Role of Angiotensin II Type 2 Receptor in Immune-Mediated Glomerulonephritis during Type 1 Receptor Blockade Am. J. Pathol., November 1, 2006; 169(5): 1577 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. De, G. Das, K. Harley, and H. Nair Review: Dual blockade of renin-angiotensin system in diabetic nephropathy: review of literature and local experience The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 23 - 28. [Abstract] [PDF]
|
|
|
|
|
|
R. Kumar and P. H Winocour Review: Dual blockade of the renin angiotensin system in diabetes -- rationale and risks The British Journal of Diabetes & Vascular Disease, September 1, 2005; 5(5): 266 - 271. [Abstract] [PDF]
|
|
|
|
 |
|
 P. K. Jacobsen Review: Preventing End-Stage Renal Disease in Diabetic Patients -- Dual Blockade of the Renin-Angiotensin System (Part II) Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 55 - 68. [Abstract] [PDF]
|
|
|
|
 |
|
 B. J Epstein and J. G Gums Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations Ann. Pharmacother., March 1, 2005; 39(3): 470 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Benigni, D. Corna, C. Zoja, L. Longaretti, E. Gagliardini, N. Perico, T. M. Coffman, and G. Remuzzi Targeted Deletion of Angiotensin II Type 1A Receptor Does not Protect Mice from Progressive Nephropathy of Overload Proteinuria J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2666 - 2674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lassila, K. K. Seah, T. J. Allen, V. Thallas, M. C. Thomas, R. Candido, W. C. Burns, J. M. Forbes, A. C. Calkin, M. E. Cooper, et al. Accelerated Nephropathy in Diabetic Apolipoprotein E-Knockout Mouse: Role of Advanced Glycation End Products J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2125 - 2138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. T.H. Lee, Z. Cao, D. M. Long, S. Panagiotopoulos, G. Jerums, M. E. Cooper, and J. M. Forbes Interactions between Angiotensin II and NF-{kappa}B-Dependent Pathways in Modulating Macrophage Infiltration in Experimental Diabetic Nephropathy J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2139 - 2151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. R. Goncalves, C. K. Fujihara, A. L. Mattar, D. M. A. C. Malheiros, I. L. Noronha, G. de Nucci, and R. Zatz Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory Am J Physiol Renal Physiol, May 1, 2004; 286(5): F945 - F954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hashimoto, Y. Maeshima, M. Satoh, M. Odawara, H. Sugiyama, N. Kashihara, H. Matsubara, Y. Yamasaki, and H. Makino Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model Am J Physiol Renal Physiol, March 1, 2004; 286(3): F516 - F525. [Abstract] [Full Text]
|
|
|
|
 |
|
 X. Zhang, M. Lassila, M. E. Cooper, and Z. Cao Retinal Expression of Vascular Endothelial Growth Factor Is Mediated by Angiotensin Type 1 and Type 2 Receptors Hypertension, February 1, 2004; 43(2): 276 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Rizkalla, J. M. Forbes, M. E. Cooper, and Z. Cao Increased Renal Vascular Endothelial Growth Factor and Angiopoietins by Angiotensin II Infusion Is Mediated by Both AT1 and AT2 Receptors J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3061 - 3071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sarlos, B. Rizkalla, C. J. Moravski, Z. Cao, M. E. Cooper, and J. L. Wilkinson-Berka Retinal Angiogenesis Is Mediated by an Interaction between the Angiotensin Type 2 Receptor, VEGF, and Angiopoietin Am. J. Pathol., September 1, 2003; 163(3): 879 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rossing, P. Jacobsen, L. Pietraszek, and H.-H. Parving Renoprotective Effects of Adding Angiotensin II Receptor Blocker to Maximal Recommended Doses of ACE Inhibitor in Diabetic Nephropathy: A randomized double-blind crossover trial Diabetes Care, August 1, 2003; 26(8): 2268 - 2274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jacobsen, S. Andersen, B. R. Jensen, and H.-H. Parving Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy J. Am. Soc. Nephrol., April 1, 2003; 14(4): 992 - 999. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
